Patent Pool May Be a Key Factor in Open RAN Adoption, Report Says
A patent pool may play a key role in the adoption of Open RAN technology, according to a recent report published by Harvard Business School Professor Josh Lerner and Bella Private Markets.
The report entitled “Accelerating innovation in connectivity: The case for an Open RAN patent pool”, which can be found here, was commissioned by Alium, a joint venture between MPEG LA and Unified Patents. Alium launched the Open RAN Patent Portfolio License last year. See https://www.alium-llc.com/blog/alium-introduces-open-ran-patent-portfolio-license
"Patent pools have historically played a critical role in supporting innovation by reducing risks around intellectual property and encouraging investment in new technologies. One such technology is Open RAN, a key component in unlocking widespread 5G adoption,” said Professor Lerner. “The Alium pool represents one effort to accelerate the adoption of Open RAN and help realize its many potential benefits."
“We appreciate the work of Josh Lerner and Bella Private Markets demonstrating a patent pool’s role in the adoption of Open RAN technology,” said Craig Thompson, a licensing executive at Alium. “While Open RAN has the potential to reshape the market for mobile telecommunications by increasing vendor diversity, lowering costs and energy consumption, facilitating wider adoption of 5G, and giving operators greater control over their networks, it relies on a crowded and complex patent landscape with little or no royalty benchmarking information. That’s where the Alium Patent Pool comes in. Based on our experience, we are confident that Alium’s Open RAN Patent Pool will reduce royalty stacking, hold-up, and expensive litigation risks, helping Open RAN implementers save billions in costs while accelerating future revenue growth, profitability, and new service deployments.”
Alium’s objective is to offer worldwide access to as many Open RAN essential patents as possible to everyone on the same terms under a single license. Alium welcomes the participation of any party with at least one patent that is essential to the Open RAN Standard. For more information, please go to https://www.alium-llc.com/licensors.
Josh Lerner and Bella Private Markets
Bella Private Markets focuses exclusively on providing solutions to the challenges facing the private capital industry. Led by Harvard Business School Professor Dr. Josh Lerner, Bella combines rigorous academic approaches with real world industry expertise to provide actionable insights for its clients. Bella focuses on complex, customized projects that require thorough analysis, whether quantitative or qualitative in nature, to help its clients improve performance, optimize operations, and chart winning strategies for the future.
Alium
Alium, a joint venture between MPEG LA and Unified Patents, supports Open RAN with the first patent pool for telecommunications infrastructure. Open RAN provides network operators with greater control and flexibility in deploying 4G and next generation 5G networks, and the Alium patent pool provides a one-stop solution to the uncertainty and risk posed by as many as tens of thousands of patents owned by numerous patent owners that cover the 3GPP standardized lower physical layer functionalities performed by radio units applying the O-RAN Alliance’s 7-2x baseband architecture split.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005684/en/
Contact information
Tom O’Reilly
Alium
Tel: 303.200.1710
tom@alium-llc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 02:00:00 EET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 23:30:00 EET | Press release
Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the cornerstone of Australia’s secure military communications since IS-22’s launch in 2012. SES will build a dedicated ground segmen
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 23:05:00 EET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 21:00:00 EET | Press release
Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain and stiffness in the global Phase 3 MANEUVER study
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 20:32:00 EET | Press release
Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112241557/en/ Ricimed - Fabentech Ricimed®, an antidote against one of the most toxic natural substances in the world In addition to supportive care, and in severe situations requiring immediate administration, Ricimed® represents a new therapeutic option for the management of acute ricin intoxication. Ricin, among the most dangerous naturally occurring substances, can cause death within hours or days regardless of the route of exposure, making it a major biological threat for many countries. Having demonstrated its ability to specifically target and neutralize ricin before irreversible damage occurs, Ricimed® is an antibody-based therapy relying on poly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom